<DOC>
	<DOCNO>NCT00558818</DOCNO>
	<brief_summary>A open-labeled phase lV study 96 week treatment period . The purpose study investigate safety efficacy clevudine patient chronically infect hepatitis B virus , HBeAg positive negative .</brief_summary>
	<brief_title>Long-term Study With Clevudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>Inclusion Criteria Patient DNA level &gt; =1 x 10^5 copies/mL within 30 day baseline . Patient document HBsAg positive &gt; 6 month . Patient ALT level &gt; =80 IU/L Women childbearing potential must negative urine ( Î²HCG ) pregnancy test take within 14 day start therapy . Exclusion Criteria . Patient currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy . Patients previously treat interferon within previous 6 month . Patients previously treat clevudine , lamivudine , adefovir , entecavir , telbivudine investigational nucleoside HBV infection . Patient history ascites , variceal hemorrhage hepatic encephalopathy . Patient coinfected HCV , HDV HIV . Patient clinical evidence decompensated liver disease hepatocellular carcinoma Patient pregnant breastfeeding . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . Patient clinically relevant history abuse alcohol drug . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic ( except HCC ) allergic disease medical illness investigator 's opinion might interfere therapy . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>